Glipizide Linked to Highest MACE-4 Risk in Individuals With Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
MONDAY, July 28, 2025 -- For individuals with type 2 diabetes (T2D) and moderate cardiovascular risk treated with metformin, the risk for major adverse cardiovascular events is highest for glipizide as a second-line therapy compared with other sulfonylureas and dipeptidyl peptidase 4 inhibitors (DPP4is), according to a study published online July 24 in JAMA Network Open.
Alexander Turchin, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a comparative effectiveness research study involving individuals with T2D and moderate cardiovascular risk treated with metformin monotherapy. A total of 48,165 individuals were eligible, of whom 18,147 started glipizide; 14,282 started glimepiride; 1,887 started glyburide; and 13,849 started a DPP4i as a second-line therapy.
The researchers found that during a median follow-up of 37 months, 3,158 individuals (6.6 percent) experienced a 4-point composite of major adverse cardiovascular events (MACE-4; myocardial infarction, ischemic stroke, heart failure hospitalization, or cardiovascular death from any of these conditions). The estimated five-year risks for MACE-4 were 8.1, 8.4, 8.6, and 9.1 percent for DPP4is, glyburide, glimepiride, and glipizide, respectively. The five-year risk ratios (95 percent confidence intervals) of MACE-4 were 1.13 (1.03 to 1.23), 1.07 (0.96 to 1.16), and 1.04 (0.83 to 1.24) for glipizide, glimepiride, and glyburide, respectively, compared with DPP4is.
"While sulfonylureas are popular and affordable diabetes medications, there is a lack of long-term clinical data on how they affect cardiac health in comparison to more neutral alternatives like dipeptidyl peptidase 4 inhibitors," Turchin said in a statement. "Our study underscores the importance of evaluating each drug in a particular pharmacological class on its own merits."
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Seniors With Certain Cardiovascular Diseases Saw Life's Essential 8 Scores Decline 2013 to 2018
WEDNESDAY, Aug. 20, 2025 -- From 2013 to 2018, older adults with heart failure, stroke, and hypertension experienced significant declines in Life's Essential 8 (LE8) scores...
Diabetes Risk Commonly Clustered Within Households
TUESDAY, Aug. 19, 2025 -- Diabetes risk is commonly clustered within households, according to a study scheduled to be presented at the annual meeting of the European Association...
Saliva Insulin Can Differentiate Hyperinsulinemia in Normoglycemic People
MONDAY, Aug. 18, 2025 -- Saliva insulin can differentiate between normal and hyperinsulinemic responses among normoglycemic adults with different body mass index (BMI) classes...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.